Cargando…

Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] ()

BACKGROUND: Focal therapy is being offered as a viable alternative for men with localised prostate cancer (PCa), but it is unclear which men may be suitable. OBJECTIVE: To determine the proportion of men with localised PCa who are potentially suitable for focal therapy. DESIGN, SETTING, AND PARTICIP...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Paras B., Anele, Chukwuemeka, Dalton, Emma, Barbouti, Omar, Stevens, Daniel, Gurung, Pratik, Arya, Manit, Jameson, Charles, Freeman, Alex, Emberton, Mark, Ahmed, Hashim U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062939/
https://www.ncbi.nlm.nih.gov/pubmed/24207133
http://dx.doi.org/10.1016/j.eururo.2013.09.045
_version_ 1782321715196461056
author Singh, Paras B.
Anele, Chukwuemeka
Dalton, Emma
Barbouti, Omar
Stevens, Daniel
Gurung, Pratik
Arya, Manit
Jameson, Charles
Freeman, Alex
Emberton, Mark
Ahmed, Hashim U.
author_facet Singh, Paras B.
Anele, Chukwuemeka
Dalton, Emma
Barbouti, Omar
Stevens, Daniel
Gurung, Pratik
Arya, Manit
Jameson, Charles
Freeman, Alex
Emberton, Mark
Ahmed, Hashim U.
author_sort Singh, Paras B.
collection PubMed
description BACKGROUND: Focal therapy is being offered as a viable alternative for men with localised prostate cancer (PCa), but it is unclear which men may be suitable. OBJECTIVE: To determine the proportion of men with localised PCa who are potentially suitable for focal therapy. DESIGN, SETTING, AND PARTICIPANTS: Our institutional transperineal template prostate-mapping (TTPM) biopsy registry of 377 men from 2006 to 2010 identified 291 consecutive men with no prior treatment. INTERVENTION: TTPM biopsies using a 5-mm sampling frame. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Suitability for focal therapy required the cancer to be (1) unifocal, (2) unilateral, (3) bilateral/bifocal with at least one neurovascular bundle avoided, or (4) bilateral/multifocal with one dominant index lesion and secondary lesions with Gleason ≤3 + 3 and cancer core involvement ≤3 mm. Binary logistic regression modelling was used to determine variables predictive for focal therapy suitability. RESULTS AND LIMITATIONS: The median age was 61 yr, and the median prostate-specific antigen was 6.8 ng/ml. The median total was 29 cores, with a median of 8 positive cores. Of 239 of 291 men with cancer, 29% (70 men), 60% (144 men), and 8% (20 men) had low-, intermediate-, and high-risk PCa, respectively. Ninety-two percent (220 men) were suitable for one form of focal therapy: hemiablation (22%, 53 men), unifocal ablation (31%, 73 men), bilateral/bifocal ablation (14%, 33 men), and index lesion ablation (26%, 61 men). Binary logistic regression modelling incorporating transrectal biopsy parameters showed no statistically significant predictive variable. When incorporating TTPM parameters, only T stage was a significant negative predictor for suitability (p = 0.001) (odds ratio: 0.001 [95% confidence interval, 0.000–0.048]). Limitations of the study include potential selection bias caused by tertiary referral practise and lack of long-term results on focal therapy efficacy. CONCLUSIONS: Focal therapy requires an accurate tool to localise individual cancer lesions. When such a test, TTPM biopsy, was applied to men with low- and intermediate-risk PCa, most of the men were suitable for a tissue preservation strategy.
format Online
Article
Text
id pubmed-4062939
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-40629392014-07-01 Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] () Singh, Paras B. Anele, Chukwuemeka Dalton, Emma Barbouti, Omar Stevens, Daniel Gurung, Pratik Arya, Manit Jameson, Charles Freeman, Alex Emberton, Mark Ahmed, Hashim U. Eur Urol Platinum Priority – Prostate Cancer BACKGROUND: Focal therapy is being offered as a viable alternative for men with localised prostate cancer (PCa), but it is unclear which men may be suitable. OBJECTIVE: To determine the proportion of men with localised PCa who are potentially suitable for focal therapy. DESIGN, SETTING, AND PARTICIPANTS: Our institutional transperineal template prostate-mapping (TTPM) biopsy registry of 377 men from 2006 to 2010 identified 291 consecutive men with no prior treatment. INTERVENTION: TTPM biopsies using a 5-mm sampling frame. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Suitability for focal therapy required the cancer to be (1) unifocal, (2) unilateral, (3) bilateral/bifocal with at least one neurovascular bundle avoided, or (4) bilateral/multifocal with one dominant index lesion and secondary lesions with Gleason ≤3 + 3 and cancer core involvement ≤3 mm. Binary logistic regression modelling was used to determine variables predictive for focal therapy suitability. RESULTS AND LIMITATIONS: The median age was 61 yr, and the median prostate-specific antigen was 6.8 ng/ml. The median total was 29 cores, with a median of 8 positive cores. Of 239 of 291 men with cancer, 29% (70 men), 60% (144 men), and 8% (20 men) had low-, intermediate-, and high-risk PCa, respectively. Ninety-two percent (220 men) were suitable for one form of focal therapy: hemiablation (22%, 53 men), unifocal ablation (31%, 73 men), bilateral/bifocal ablation (14%, 33 men), and index lesion ablation (26%, 61 men). Binary logistic regression modelling incorporating transrectal biopsy parameters showed no statistically significant predictive variable. When incorporating TTPM parameters, only T stage was a significant negative predictor for suitability (p = 0.001) (odds ratio: 0.001 [95% confidence interval, 0.000–0.048]). Limitations of the study include potential selection bias caused by tertiary referral practise and lack of long-term results on focal therapy efficacy. CONCLUSIONS: Focal therapy requires an accurate tool to localise individual cancer lesions. When such a test, TTPM biopsy, was applied to men with low- and intermediate-risk PCa, most of the men were suitable for a tissue preservation strategy. Elsevier Science 2014-07 /pmc/articles/PMC4062939/ /pubmed/24207133 http://dx.doi.org/10.1016/j.eururo.2013.09.045 Text en © 2013 European Association of Urology. Published by Elsevier B.V. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Platinum Priority – Prostate Cancer
Singh, Paras B.
Anele, Chukwuemeka
Dalton, Emma
Barbouti, Omar
Stevens, Daniel
Gurung, Pratik
Arya, Manit
Jameson, Charles
Freeman, Alex
Emberton, Mark
Ahmed, Hashim U.
Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] ()
title Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] ()
title_full Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] ()
title_fullStr Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] ()
title_full_unstemmed Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] ()
title_short Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] ()
title_sort prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy [image: see text] ()
topic Platinum Priority – Prostate Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062939/
https://www.ncbi.nlm.nih.gov/pubmed/24207133
http://dx.doi.org/10.1016/j.eururo.2013.09.045
work_keys_str_mv AT singhparasb prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext
AT anelechukwuemeka prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext
AT daltonemma prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext
AT barboutiomar prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext
AT stevensdaniel prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext
AT gurungpratik prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext
AT aryamanit prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext
AT jamesoncharles prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext
AT freemanalex prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext
AT embertonmark prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext
AT ahmedhashimu prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext